All In Biotech

Drug Trial Radar · NCT05005728

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

72

Actual

Start

Oct 22, 2021

Primary completion

Jun 10, 2025

Study completion Jun 10, 2025

Sponsor

Lead sponsor
Xencor, Inc.Industry
Sponsor type
Industry
First posted
Aug 13, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed on prior therapy.

Conditions

  • Metastatic Castration-Resistant Prostate Cancer

Interventions

  • vudalimab + carboplatin + cabazitaxelCombination product

    Vudalimab IV, carboplatin IV, cabazitaxel IV

  • vudalimab + olaparibCombination product

    Vudalimab IV, olaparib oral

  • vudalimab monotherapyBiological

    Vudalimab IV

  • vudalimab + docetaxelCombination product

    Vudalimab IV, docetaxel IV

  • vudalimab + cabazitaxel or docetaxelCombination product

    Vudalimab IV, cabazitaxel or docetaxel IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (safety and tolerability of vudalimab)Time frame: 8 weeks

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Alaska Oncology and Hematology

    Anchorage, Alaska

  • Palo Verde Hematology Oncology

    Glendale, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • City of Hope

    Duarte, California

  • VA Greater Los Angeles

    Los Angeles, California

  • University of California, San Diego

    San Diego, California

  • Rocky Mountain Cancer Centers

    Lone Tree, Colorado

  • Mayo Clinic

    Jacksonville, Florida

  • The University of Chicago Medical Center

    Chicago, Illinois

  • University of Iowa Hospitals & Clinics

    Iowa City, Iowa

  • University of Kansas Clinical Research Center

    Fairway, Kansas

  • Mayo Clinic

    Rochester, Minnesota

  • GU Research Network/Urology Cancer Center

    Omaha, Nebraska

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • XCancer New Mexico Oncology Hematology Consultants, Ltd.

    Albuquerque, New Mexico

  • Columbia University

    New York, New York

  • Montefiore Medical Center

    The Bronx, New York

  • Northwest Cancer Specialists

    Tigard, Oregon

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania

  • Carolina Urologic Research Center

    Myrtle Beach, South Carolina

  • SCRI Oncology Partners

    Nashville, Tennessee

  • Texas Oncology-Central South

    Weslaco, Texas

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Virginia Oncology Associates

    Norfolk, Virginia

  • University of Washington/Seattle Cancer Care/Alliance

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.